This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
1 - 2 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Serum or EDTA plasma
1.5 mL (Note: This volume does not allow for repeat testing.)
Gel-barrier tube, red top tube or lavender-top (EDTA) tube
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
Non-EDTA plasma specimen; PST gel-barrier tube
Screening of pregnant women for hepatitis B virus (HBV) infection to identify neonates who are at risk of acquiring hepatitis B during the perinatal period.
Patients who are negative for HBsAg may still have acute hepatitis B infection. A nonreactive/negative result in individuals with prior exposure to hepatitis B may be due to antigen levels below the detection limit of the assay or lack of antigen reactivity to the antibodies in the assay used. In cases with strong clinical suspicion of viral hepatitis, testing should not be limited to detecting HBsAg, but should include a battery of tests to evaluate different stages of acute and convalescent hepatitis, including detection of antibodies to hepatitis B core antigen (anti-HBc) and HBV DNA.
Immunochemiluminometric assay (ICMA)
Hepatitis B surface antigen (HBsAg) is a distinctive serological marker of acute or chronic hepatitis B infection. HBsAg is the first antigen to appear following infection with HBV and is generally detected 1-10 weeks after the onset of clinical symptoms. HBsAg assays are routinely used to diagnose suspected HBV infection and monitor the status of infected individuals to determine whether the infection has resolved or the patient has become a chronic carrier of the virus. In patients that recover from HBV infection, HBsAg is undetectable 3-5 months after the onset of infection. In patients with chronic HBV infection, HBsAg remains detectable for life. Prenatal HBsAg screening has been recommended so that newborns from HBV carrier mothers may obtain prophylactic treatment.
Refer to https://www.cdc.gov/hepatitis/hbv/pdfs/PrenatalHBsAgTesting.pdf for additional information on HBV testing recommendations in pregnant women.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|144510||HBV Prenatal Screen||006510||HBsAg Screen||5196-1|
|Reflex Table for HBsAg Screen|
|Order Code||Order Name||Result Code||Result Name||UofM||Result LOINC|
|Reflex 1||000000||16105||000000||16105||HBsAg Confirmation|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf